- Home
- RLMD vs SLGL Comparison
RLMD vs SLGL Comparison
Compare RLMD & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLMD
- SLGL
- Stock Information
- Founded
- RLMD 2004
- SLGL 1997
- Country
- RLMD United States
- SLGL Israel
- Employees
- RLMD N/A
- SLGL N/A
- Industry
- RLMD Biotechnology: Pharmaceutical Preparations
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- RLMD Health Care
- SLGL Health Care
- Exchange
- RLMD Nasdaq
- SLGL Nasdaq
- Market Cap
- RLMD 20.3M
- SLGL 19.3M
- IPO Year
- RLMD N/A
- SLGL 2018
- Fundamental
- Price
- RLMD $0.64
- SLGL $12.48
- Analyst Decision
- RLMD Buy
- SLGL Buy
- Analyst Count
- RLMD 3
- SLGL 1
- Target Price
- RLMD $5.00
- SLGL $40.00
- AVG Volume (30 Days)
- RLMD 211.8K
- SLGL 11.4K
- Earning Date
- RLMD 08-11-2025
- SLGL 08-15-2025
- Dividend Yield
- RLMD N/A
- SLGL N/A
- EPS Growth
- RLMD N/A
- SLGL N/A
- EPS
- RLMD N/A
- SLGL N/A
- Revenue
- RLMD N/A
- SLGL $12,103,000.00
- Revenue This Year
- RLMD N/A
- SLGL N/A
- Revenue Next Year
- RLMD N/A
- SLGL $31.17
- P/E Ratio
- RLMD N/A
- SLGL N/A
- Revenue Growth
- RLMD N/A
- SLGL 603.66
- 52 Week Low
- RLMD $0.24
- SLGL $3.34
- 52 Week High
- RLMD $4.02
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- RLMD 50.91
- SLGL 85.60
- Support Level
- RLMD $0.60
- SLGL $10.77
- Resistance Level
- RLMD $0.74
- SLGL $12.90
- Average True Range (ATR)
- RLMD 0.06
- SLGL 0.92
- MACD
- RLMD 0.00
- SLGL 0.43
- Stochastic Oscillator
- RLMD 44.19
- SLGL 92.05
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.